Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Home Depot

NVIDIA

Starbucks

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Moderna among others.

Moderna Ranked Among Today's Trending Stocks As Pfizer Gets Fully Approved By FDA

Pfizer

Pfizer soared 4%, while its German vaccine partner, BioNTech, climbed more than 10%.

Pfizer And Moderna Rally After FDA Grants Full Approval To Pfizer's Covid-19 Vaccine

Costco

Carnival

Coca-Cola

Calpers bought more Moderna, Costco, and Carnival stock, and cut back on Coca-Cola stock in the second quarter.

Largest U.S. Pension Bet Big on Covid-Vaccine Maker Moderna, Costco Stock

Will Moderna Be a Trillion-Dollar Stock by 2022?

BioNTech SE

Novavax

The U.S. is ramping up its ability to produce more COVID-19 vaccines.

Why Moderna, BioNTech, and Novavax Stocks Climbed Today

The U.S. health officials are reviewing reports that Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine may be linked to a higher risk of a rare heart condition, Washington Post reported, citing people familiar with the matter. The investigation involves the FDA and the Centers for Disease Control and Prevention, focusing on Canadian data suggesting the Moderna vaccine may be associated with a higher risk of heart inflammation than the Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) vaccine, especially for males below the age of 30.

FDA Reviews If Moderna's COVID-19 Shot Is Associated With Higher Heart Inflammation Risk

Moderna stock has rallied from around $104 per share at the end of 2020, to about $485 as of Monday, an increase of over 4.5x. This compares to the S&P 500 which is up by just about 20% over the same period.

What Drove Moderna Stock From $100 To Near $500?

Moderna's (MRNA) COVID-19 vaccine is being probed for higher risk of heart inflammation compared to Pfizer's vaccine, per a Washington Post article.

Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?

3 Reasons BioNTech Isn't Nearly as Big as Moderna

A couple of developments likely factored into the declines for these vaccine stocks.

Why Moderna, BioNTech, and Novavax Stocks Sank Today

Scientists have been trying to find an effective vaccine for HIV for years. Researchers hope mRNA is the future.

Moderna to start testing new HIV vaccines

Johnson & Johnson

In order to provide better protection to the American people from rising COVID-19 cases due to the surge of the Delta variant, U.S. health officials are recommending use of a booster dose for individuals starting this fall.

US Set to Receive COVID-19 Vaccine Booster Dose Next Month

The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.

Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now

Health officials with the Biden administration say another shot is needed to maximize protection.

US to start offering Pfizer, Moderna booster shots for COVID-19 in September

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Moderna (MRNA) Just Overtook the 20-Day Moving Average

BURLINGTON, Mass., Aug. 18, 2021 /PRNewswire/ -- Azzur Cleanrooms on Demand™ ("COD"), an Azzur Group company, market-leading providers for early-phase life sciences GxP manufacturing, today announced that they are expanding their ongoing business relationship with the life sciences company Moderna TX, Inc. ("Moderna").

Azzur Group and Moderna Expand Their Ongoing Relationship

Moderna is the star stock of 2021 maintaining its position as the S&P 500's top performer.

Moderna cements lead as S&P's top stock of 2021

The vaccine stock could be priced for even more than perfection.

Why 1 Analyst Predicts Moderna Stock Will Plunge Nearly 70%

Blink Charging

Freeport-McMoRan

Pinduoduo Inc - ADR

With the stock market looking frothy, these are four high beta stocks to avoid. Instead, go overweight on defensive stocks.

4 High Beta Stocks to Avoid on Possibility of a Market Correction

Moderna Inc (NASDAQ: MRNA) shares are reversing course and are higher Tuesday. UK Expands Authorization: The UK drug regulator — the Medicines and Healthcare Products Regulatory Agency — announced Tuesday it has expanded the authorization given to Moderna's COVID-19 vaccine to include the adolescent population.

Here's Why Moderna's Shares Are Rebounding From Recent Losses

Fortinet

Generac Holdings

Gartner

Nucor

SPDR S&P 500 ETF Trust

The S&P 500 Index has been hitting a series of record highs, braving a myriad of hurdles.

5 Stocks Leading the Rally in S&P 500 ETF

Moderna (MRNA) doses first patient in phase I/II study with mRNA-3705 for the treatment of a rare multi-organ disorder. The company also revises the supply agreement with the Canadian Government for its COVID vaccine.

Moderna (MRNA) Begins Rare Disease Study, Inks Supply Agreement

Moderna stock is up by about 2.5x year-to-date, trading at levels of about $390 per share as of Friday. The rally comes on the back of Moderna's recent inclusion into the S&P 500 index and the emergence of new virus variants which are making a strong case for booster doses of Covid-19 shots.

Moderna Stock At $400. What Are The Risks?

Moderna has been a great investment over the last year, but past returns do not equate to future returns.

News for Moderna Stock (MRNA)